As  previously reported, the Federal Court of Appeal (FCA) allowed in part Apotex's appeal of a decision awarding Eli Lilly over $100 million for Apotex's infringement of eight process patents related to the antibiotic cefaclor. The FCA rejected Apotex's argument that a non-infringing alternative would have been available to Apotex during the relevant period. The FCA remitted the decision to the Federal Court for reconsideration solely on the issue of prejudgment interest: Apotex v Eli Lilly2018 FCA 217. On January 22, 2019, Apotex applied to the Supreme Court of Canada for leave to appeal (Docket No. 38485).

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.